LivaNova (LIVN) Free Cash Flow Growth (1y) (2017 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | -1.82% |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 226.77% |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | 9.73% |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | -51.69% |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | -109.40% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 133.09% |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 363.84% |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | 108.16% |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 29.12% |
| 10 | LivaNova | 4.03 Bn | 3.45 Bn | 243.75 Mn | -92.97% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -92.97% |
| Dec 31, 2025 | -26.55% |
| Sep 30, 2025 | 89.29% |
| Jun 30, 2025 | 53.12% |
| Mar 31, 2025 | 267.74% |
| Dec 31, 2024 | 66.43% |
| Sep 30, 2024 | 248.77% |
| Jun 30, 2024 | 232.23% |
| Mar 31, 2024 | -72.59% |
| Dec 31, 2023 | 328.87% |
| Sep 30, 2023 | -68.18% |
| Jun 30, 2023 | -44.14% |
| Mar 31, 2023 | -36.57% |
| Dec 31, 2022 | -63.05% |
| Sep 30, 2022 | 43.11% |
| Jun 30, 2022 | -185.13% |
| Mar 31, 2022 | 83.02% |
| Dec 31, 2021 | -14.84% |
| Sep 30, 2021 | 1,228.31% |
| Jun 30, 2021 | 167.76% |
| Mar 31, 2021 | 109.82% |
| Dec 31, 2020 | 705.21% |
| Sep 30, 2020 | 97.78% |
| Jun 30, 2020 | -16.06% |
| Mar 31, 2020 | -2,943.32% |
| Dec 31, 2019 | -162.64% |
| Sep 30, 2019 | -310.53% |
| Jun 30, 2019 | -213.71% |
| Mar 31, 2019 | -125.90% |
| Dec 31, 2018 | -8.29% |
| Sep 30, 2018 | 18.80% |
| Jun 30, 2018 | 338.82% |
| Mar 31, 2018 | -43.27% |
| Dec 31, 2017 | -72.12% |
| Sep 30, 2017 | 34.84% |
| Mar 31, 2017 | 1,652.63% |